See more : Eimco Elecon (India) Limited (EIMCOELECO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Aleafia Health Inc. (ALEAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aleafia Health Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ParkHotels (PARKHOTELS.NS) Income Statement Analysis – Financial Results
- Royal Boskalis Westminster N.V. (BOKA.AS) Income Statement Analysis – Financial Results
- RTG Mining Inc. (RTGGF) Income Statement Analysis – Financial Results
- China Life Insurance Company Limited (CILJF) Income Statement Analysis – Financial Results
- Suzhou Hengmingda Electronic Technology Co., Ltd. (002947.SZ) Income Statement Analysis – Financial Results
Aleafia Health Inc. (ALEAF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aleafiahealth.com
About Aleafia Health Inc.
Aleafia Health Inc. operates as a cannabis health and wellness products and services company in Canada and internationally. Its product portfolio includes cannabis oils, capsules, edibles, cannabis-infused sublingual strips, and vape cartridges; bath bombs and soft gels; hang dried, hand trimmed, long cured, and small batch dried flower; and concentrates. In addition, the company owns and operates a virtual network of medical cannabis clinics staffed through physicians and nurse practitioners; and operates education centers. It offers its products under the Divvy, Sunday Market, Bogart's Kitchen, Noon & Night, Nith & Grand, Kin Slips, and Emblem brands. The company is headquartered in Concord, Canada.
Metric | 2022 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 42.85M | 44.54M | 16.35M | 3.33M | 15.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 36.85M | 50.15M | -4.43M | 541.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 6.00M | -5.61M | 20.78M | 2.79M | 15.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 14.00% | -12.59% | 127.10% | 83.73% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 17.70M | 31.94M | 38.85M | 20.01M | 9.53M | 65.10K | 130.05K | 178.28K | 515.61K | 2.57M | 484.84K | 86.27K | 0.00 | 0.00 |
Selling & Marketing | 2.46M | 0.00 | 0.00 | 933.43K | 114.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 20.17M | 31.94M | 38.85M | 20.94M | 9.65M | 65.10K | 130.05K | 178.28K | 515.61K | 2.57M | 484.84K | 86.27K | 160.45K | 87.16K |
Other Expenses | 3.37M | 8.06M | 5.91M | 1.66M | 60.46K | 52.98K | 16.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 23.54M | 40.00M | 44.77M | 22.60M | 9.71M | 65.10K | 146.68K | 178.28K | 515.61K | 2.57M | 484.84K | 86.27K | 160.45K | 87.16K |
Cost & Expenses | 60.39M | 90.15M | 40.33M | 23.14M | 9.71M | 65.10K | 146.68K | 178.28K | 515.61K | 2.57M | 484.84K | 86.27K | 160.45K | 87.16K |
Interest Income | 0.00 | 0.00 | 417.00K | 169.84K | 0.00 | 0.00 | 0.00 | 61.00 | 169.00 | 4.14K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 9.36M | 403.53M | 6.38M | 0.00 | 0.00 | 2.42K | 1.40K | 0.00 | 1.71K | 0.00 | 14.70K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 6.57M | 10.16M | 6.63M | 1.56M | 60.46K | 0.00 | 0.00 | 61.00 | 169.00 | 4.14K | -70.00K | 0.00 | 951.64K | 0.00 |
EBITDA | -10.97M | 163.92M | -17.35M | -18.25M | -9.63M | -12.12K | -146.68K | -178.22K | -515.44K | -2.57M | -554.84K | -86.27K | 791.19K | -87.16K |
EBITDA Ratio | -25.61% | 368.01% | -106.12% | -548.10% | -61,089.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -17.54M | 153.75M | -23.98M | -19.81M | -9.69M | -12.12K | -146.68K | -178.28K | -515.61K | -2.57M | -484.84K | -86.27K | -160.45K | -87.16K |
Operating Income Ratio | -40.93% | 345.19% | -146.68% | -594.92% | -61,473.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -17.07M | -403.53M | -12.67M | 269.84K | 0.00 | 2.13K | -1.40K | -2.97M | 7.54K | 8.31K | 57.00K | 0.00 | -951.64K | 0.00 |
Income Before Tax | -34.61M | -249.78M | -36.65M | -19.54M | -9.69M | -9.98K | -148.08K | -3.14M | -509.62K | -2.56M | -512.55K | -86.27K | -1.11M | -87.16K |
Income Before Tax Ratio | -80.77% | -560.77% | -224.13% | -586.81% | -61,473.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 7.71M | -2.54M | 2.96M | -1.01M | 0.00 | -4.55K | 0.00 | 2.97M | -7.71K | -12.45K | -10.31K | 0.00 | 951.64K | 0.00 |
Net Income | -42.32M | -247.24M | -39.61M | -18.53M | -9.69M | -5.44K | -148.08K | -3.14M | -509.62K | -2.56M | -502.24K | -86.27K | -1.11M | -87.16K |
Net Income Ratio | -98.77% | -555.07% | -242.23% | -556.55% | -61,473.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -0.11 | -0.85 | -0.18 | -0.16 | -0.24 | -0.01 | -0.15 | -3.15 | -0.57 | -3.50 | -1.17 | -0.20 | -14.51 | -0.20 |
EPS Diluted | -0.11 | -0.85 | -0.18 | -0.16 | -0.24 | -0.01 | -0.15 | -3.15 | -0.57 | -3.50 | -1.17 | -0.20 | -14.51 | -0.20 |
Weighted Avg Shares Out | 386.36M | 291.59M | 215.62M | 117.16M | 39.98M | 998.95K | 998.95K | 998.95K | 898.88K | 730.95K | 430.20K | 430.20K | 76.63K | 430.20K |
Weighted Avg Shares Out (Dil) | 386.36M | 291.59M | 215.62M | 117.16M | 39.98M | 998.95K | 998.95K | 998.95K | 898.88K | 730.95K | 430.20K | 430.20K | 76.63K | 430.20K |
Aleafia Health Announces Closing of $10 Million Credit Facility
Cantor: 'Aleafia Continues To Post Solid Momentum,' Firm Bullish But Lowers Price Target Due To Cannabis Sector Derating
Aleafia Health, Inc. (ALEAF) CEO Geoffrey Benic on Q2 2021 Results - Earnings Call Transcript
Aleafia Health Reports Strong 2021 Second Quarter Financial Results with 53% Sequential Increase in Cannabis Net Revenue
Aleafia Health to Announce 2021 Second Quarter Results
Aleafia Health Announces the Appointment of Mark J. Sandler as Board Chair
Aleafia Health Launches Premium Cannabis Brand Nith & Grand
Cannabis Industry Investor Presentations Now Available for On-Demand Viewing
Aleafia Health Announces Results of Annual General Meeting
Aleafia Health Announces the Passing of Director Daniel Milliard
Source: https://incomestatements.info
Category: Stock Reports